On 15 February 2023, the Commission requested an opinion from the European Chemicals Agency (‘the Agency’) in accordance with Article 36(2) of Regulation (EU) No 528/2012. With regard to efficacy, the Commission asked the Agency to indicate whether it can be considered that the tests provided in the authorisation application show efficacy of the biocidal product family for the intended use, if the deviations from the pass criteria of EN 1276:2009 are acceptable and properly justified and if the modified test EN 1276:2009 provided in the application as simulated-use test can be considered as simulating appropriately the practical conditions of use. Considering that at the moment of submission of the application very limited guidance concerning product-type 5 products was available, the Commission considered it appropriate that the results of an additional simulated-use study provided by the applicant after the referral of the disagreement to the Commission, on 10 May 2021, be taken into account when assessing the efficacy of the biocidal product family. Consequently, the Commission asked the Agency to indicate whether, taking into account the additional test results provided by the applicant in May 2021, it can be considered that efficacy of the products of the biocidal product family for the intended use is demonstrated. Finally, the Commission asked the Agency to indicate the correct classification for environmental hazards of the products of the biocidal product family in accordance with Regulation (EC) No 1272/2008.
Recital 10, Decision_act (EU) 2023/2672
In forcesince 27 Nov 2023